Bristol-Myers Insider Arrest Followed Probe of Deal

U.S. regulators were so suspicious of the circumstances surrounding Gilead Sciences Inc.’s Nov. 21 announcement it was buying Pharmasset Inc. for $11 billion that they opened an insider-trading investigation that day.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.